- Global Pharma News & Resources
21-Jun-2021 - 23-Jun-2021

BCMA Targeted Therapies

Targeting BCMA with therapeutics such as ADCs, bispecific T-cell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge potential. The race for an approval within the crowded BCMA space has been hotly contested in recent years, and despite GSK's ADC, Blenrep, gaining approval in 2020 first, BCMA-targeted CAR-T and BiTe therapies continue to find their place.

With such a well validated target, rapid advances and growing excitement in the field, the inaugural BCMA Targeted Therapies Summit is industry's first dedicated discussion and networking forum focused on bringing together the thought-leaders within the BCMA field to share the latest scientific progress and address the current challenges drug developers are facing.

Developed with experts from Amgen, Kite Pharma and Legend Bio and other leading organizations, join 80+ of your peers and be part of this unique opportunity to engage in cross-industry discussions. Hear from over 20 experts sharing preclinical data for next generation BCMA targeted therapies, bringing in the patient perspective and exploring efficacy of patient response from the clinic.